Innovative Approach Shows Promise Against Synovial Sarcoma Using Protein-Blocking Drugs

The Synovial Sarcoma Foundation is dedicated to supporting cutting-edge research that advances treatment options for this rare and aggressive cancer. Recent findings published in The EMBO Journal highlight a promising new strategy: using drug blockers to target a problematic protein involved in synovial sarcoma’s genetics.

Synovial sarcoma primarily develops in soft tissues such as muscles and ligaments near large joints like the knees. It affects approximately 800 to 1,000 people yearly in the United States, most often adolescents and young adults. While early diagnosis before metastasis can improve outcomes, nearly 20% of cases are diagnosed at an advanced stage, with cancer spread to the lungs being common. The five-year survival rate remains 50–60%, underscoring the urgent need for more effective targeted therapies.

Researchers from Sanford Burnham Prebys Medical Discovery Institute, UCLA, UC San Diego, and the University of Edinburgh have made significant progress by leveraging public genomic data to identify vulnerabilities in synovial sarcoma cells. Their work focused on the genetic dependencies crucial for tumor growth and survival.

By comparing publicly available data with laboratory experiments on cell cultures and mouse models, the scientists identified the SUMO2 gene as a key player. This gene encodes a protein called small ubiquitin-like modifier 2 (SUMO2), which was found to be essential for synovial sarcoma cell viability and was activated by the disease’s hallmark mutation involving the SS18::SSX fusion oncoprotein.

Building on this discovery, the team tested a drug called TAK-981 designed to inhibit SUMO2 activity. The results were promising: drug treatment impaired the growth of synovial sarcoma cells and decreased the activity of cancer-driving genes, including the SS18::SSX fusion oncoprotein itself. Notably, SUMO2 inhibition also lowered the levels of this oncoprotein, which drives tumor development.

“Developing targeted therapies for synovial sarcoma has been hampered by our limited understanding of its underlying mechanisms,” said Dr. Rema Iyer, lead author of the study. “Our findings show that SUMO2 inhibition is an attractive therapeutic strategy.”

According to senior author Dr. Ani Deshpande, “SUMO2 inhibitors like TAK-981 may be effective on their own or in combination with existing chemotherapy, and prior preclinical studies suggest they could be a valuable addition in clinical settings.”

The Synovial Sarcoma Foundation continues to support research innovations like this, which promise more effective, targeted treatments. We remain committed to advocating for studies that bring hope to patients and families affected by this challenging disease.

For more details on this research, view the original publication in The EMBO Journal.

Sources: Sanford Burnham Prebys, MedicalXpress.com